Pieris Pharmaceuticals, Inc. (PIRS): Price and Financial Metrics

Pieris Pharmaceuticals, Inc. (PIRS): $1.73

0.04 (+2.37%)

POWR Rating

Component Grades













Add PIRS to Watchlist
Sign Up

Industry: Biotech



in industry


  • PIRS scores best on the Sentiment dimension, with a Sentiment rank ahead of 80.28% of US stocks.
  • The strongest trend for PIRS is in Quality, which has been heading up over the past 179 days.
  • PIRS's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

PIRS Stock Summary

  • Of note is the ratio of Pieris Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 7.68% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Pieris Pharmaceuticals Inc is higher than it is for about merely 18.14% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PIRS comes in at -25.02% -- higher than that of only 15.4% of stocks in our set.
  • Stocks that are quantitatively similar to PIRS, based on their financial statements, market capitalization, and price volatility, are AUTL, ARDS, ABUS, XCUR, and AYLA.
  • Visit PIRS's SEC page to see the company's official filings. To visit the company's web site, go to www.pieris.com.

PIRS Valuation Summary

  • In comparison to the median Healthcare stock, PIRS's EV/EBIT ratio is 118.09% lower, now standing at -5.3.
  • Over the past 81 months, PIRS's price/sales ratio has gone up 0.9.
  • PIRS's price/sales ratio has moved up 0.9 over the prior 81 months.

Below are key valuation metrics over time for PIRS.

Stock Date P/S P/B P/E EV/EBIT
PIRS 2021-08-31 15.2 7.7 -7.4 -5.3
PIRS 2021-08-30 14.0 7.1 -6.9 -4.7
PIRS 2021-08-27 12.9 6.6 -6.3 -4.2
PIRS 2021-08-26 12.5 6.4 -6.2 -4.0
PIRS 2021-08-25 12.3 6.2 -6.0 -3.9
PIRS 2021-08-24 11.7 5.9 -5.7 -3.6

PIRS Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -48.45%.
  • Its 2 year net income to common stockholders growth rate is now at -17.32%.
  • Its 3 year revenue growth rate is now at 745.63%.
PIRS's revenue has moved down $13,298,000 over the prior 15 months.

The table below shows PIRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 31.418 -7.66 -45.738
2021-09-30 24.852 -10.133 -50.606
2021-06-30 23.734 -3.219 -48.353
2021-03-31 31.695 -42.903 -37.805
2020-12-31 29.323 -45.896 -37.23
2020-09-30 44.716 -46.453 -26.431

PIRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PIRS has a Quality Grade of C, ranking ahead of 27.39% of graded US stocks.
  • PIRS's asset turnover comes in at 0.193 -- ranking 490th of 561 Business Services stocks.
  • NXTD, ATVI, and AEYE are the stocks whose asset turnover ratios are most correlated with PIRS.

The table below shows PIRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.193 1 -1.697
2021-03-31 0.279 1 -0.852
2020-12-31 0.254 1 -0.693
2020-09-30 0.359 1 -0.373
2020-06-30 0.456 1 -0.199
2020-03-31 0.398 1 -0.367

PIRS Price Target

For more insight on analysts targets of PIRS, see our PIRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.50 Average Broker Recommendation 1.25 (Strong Buy)

PIRS Stock Price Chart Interactive Chart >

Price chart for PIRS

PIRS Price/Volume Stats

Current price $1.73 52-week high $6.15
Prev. close $1.69 52-week low $1.61
Day low $1.64 Volume 399,200
Day high $1.75 Avg. volume 548,555
50-day MA $2.66 Dividend yield N/A
200-day MA $3.66 Market Cap 128.19M

Pieris Pharmaceuticals, Inc. (PIRS) Company Bio

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is based in Boston, Massachusetts.

PIRS Latest News Stream

Event/Time News Detail
Loading, please wait...

PIRS Latest Social Stream

Loading social stream, please wait...

View Full PIRS Social Stream

Latest PIRS News From Around the Web

Below are the latest news stories about Pieris Pharmaceuticals Inc that investors may wish to consider to help them evaluate PIRS as an investment opportunity.

Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022

BOSTON,MA / ACCESSWIRE /February 23,2022/Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2021 investor call on Tuesday, March 1, 2022 at 8:00 AM EST to discuss financial results and provide a corporate update.

Yahoo | February 23, 2022

Companies Like Pieris Pharmaceuticals (NASDAQ:PIRS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 4, 2022

HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors

Brings Significant Operational Experience in Building Therapeutic Drug Development BusinessesTUCSON, Ariz., Jan. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed biopharmaceutical industry veteran Christopher Kiritsy to its Board of Directors. Currently the Managing Member of Precision Kapital, LLC, a private investment a

Yahoo | January 28, 2022

3 Biotechs That Will Soar Regardless of COVID-19

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

Yahoo | January 27, 2022

2 Risky Growth Stocks That Could Make You Filthy Rich

Growth stocks, on balance, have fallen out of favor in recent months. Political gridlock in Washington, D.C., historically high inflation rates, and concerns about an interest rate increase have dampened investors' appetite for risk. Which unloved biotech stocks should risk-tolerant investors have on their radar right now?

Yahoo | January 16, 2022

Read More 'PIRS' Stories Here

PIRS Price Returns

1-mo -38.21%
3-mo -44.01%
6-mo -47.58%
1-year -49.71%
3-year -60.77%
5-year -62.55%
YTD -54.23%
2021 51.20%
2020 -30.94%
2019 36.09%
2018 -64.77%
2017 435.46%

Continue Researching PIRS

Want to see what other sources are saying about Pieris Pharmaceuticals Inc's financials and stock price? Try the links below:

Pieris Pharmaceuticals Inc (PIRS) Stock Price | Nasdaq
Pieris Pharmaceuticals Inc (PIRS) Stock Quote, History and News - Yahoo Finance
Pieris Pharmaceuticals Inc (PIRS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6627 seconds.